Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216043 | 1.00 | ALDH1A1 (0.39) | ALDH1A1BACE1CA12CA1CA2 | |
| SCHEMBL19876132 | 0.79 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL3867828 | 0.79 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL13488 | 0.77 | CES2 (0.36) | — | |
| SCHEMBL13617977 | 0.75 | TDP1 (0.36) | ALDH1A1 | |
| SCHEMBL16249712 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL29561813 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL3876173 | 0.75 | TSHR (0.36) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL112835 | 0.75 | ALDH1A1 (0.43) | ALDH1A1BACE1CA12CA1CA2 | |
| SCHEMBL5513611 | 0.73 | ALDH1A1 (0.45) | ALDH1A1BACE1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-115768750-A | GCN2 modulator compounds | 阿莱斯塔治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4107146-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2022-12-28 | — | — | EP | disclosed |
| CN-103102349-B | Kinases inhibitor and combinations thereof and purposes | 北京赛林泰医药技术有限公司 | 2017-03-15 | — | — | CN | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2780341-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Centaurus Biopharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | ALDH1A1 4260/4885BACE1 4366/4885CA12 4051/4885 |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | MAP3K20, MAP3K1, PRKCH | ALDH1A1 4445/4885BACE1 1749/4885CA12 4677/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | ALDH1A1 4030/4885BACE1 4154/4885CA12 4797/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | ALDH1A1 4164/4885BACE1 1893/4885CA12 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.